Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus WYAMYCIN E.
E.E.S. 200 vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic